MPM Oncology Impact Management »

Alkermes shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Alkermes (ALKS) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Alkermes

Tip: Access up to 7 years of quarterly data

All positions including Alkermes held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alkermes by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $13M 558k 24.10

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Alkermes

BlackRock
BlackRock
Vanguard Group
T. Rowe Price Associates
State Street Corporation
Renaissance Technologies
Baker Bros. Advisors
Pacer Advisors
Geode Capital Management
Deep Track Capital
PRIMECAP Management Company
American Century Companies
Commodore Capital
Dimensional Fund Advisors
Armistice Capital

View all funds holding Alkermes